Fig. 5: In vitro and in vivo synergistic effects of tazemetostat and ferroptosis inducers. | Cell Death & Disease

Fig. 5: In vitro and in vivo synergistic effects of tazemetostat and ferroptosis inducers.

From: A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis

Fig. 5

A, B mRNA expression of GPX4 and SLC7A11 in ACC cell lines treated for 48 h with tazemetostat (TAZ 5 µM). C, D Cell viability of tumor cell lines treated for 48 h with TAZ (5 μM) and RSL3 (1 µM, for the last 4 h) and their combinations. E Schematic representation of xenograft experiment setup. F, G Images of explanted xenograft tumors (F) and relative tumor weight graphs (G). H, I mRNA expression of GPX4 and SLC7A11 in xenografts tumor samples. Data were expressed as means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 ****p < 0.0001.

Back to article page